⌘K
Loading ticker…
Arrowhead Research Corporation · Healthcare · Pharmaceutical Products
As of 2026-06-26, Arrowhead Research Corporation (ARWR) has a 3-month relative strength percentile of 80 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 84. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.4%, relative volume 11.23×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 80, Market Stance is mixed at 47, A/D rating E
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ARWR is in a stage 2 uptrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 4.5% / 32.8%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
ARWR is held by 11 ETFs as of Mar 2026. Top owner: IJH at 0.27% weight, $291M notional. Top 3 carry $763M.
Top 10 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| IJHiShares Core S&P Mid-Cap ETF | 0.27% | $291M |
| VTIVanguard Total Stock Market ETF | 0.01% | $265M |
| IWMiShares Russell 2000 ETF | 0.29% | $207M |
| VBVanguard Small Cap ETF | 0.12% | $192M |
| VBKVanguard Small-Cap Growth ETF | 0.28% | $108M |
| VXFVanguard Extended Market ETF | 0.12% | $98M |
| XBIState Street SPDR S&P Biotech ETF | 1.23% | $91M |
| IWOiShares Russell 2000 Growth ETF | 0.57% | $69M |
| MDYState Street SPDR S&P MIDCAP 400 ETF Trust | 0.27% | $66M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.01% | $11M |
Showing 10 of 11 ETF owners.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARWR Jan avg: 0.34% median: 4.67% win: 75% σ: 9.40% n: 4 2022-04-12 → 2026-05-29 | ARWR Feb avg: -5.33% median: -6.28% win: 0% σ: 3.91% n: 4 2022-04-12 → 2026-05-29 | ARWR Mar avg: -16.45% median: -16.13% win: 0% σ: 13.64% n: 4 2022-04-12 → 2026-05-29 | ARWR Apr avg: 6.52% median: 9.03% win: 60% σ: 23.99% n: 5 2022-04-12 → 2026-05-29 | ARWR May avg: 0.30% median: 1.46% win: 60% σ: 12.72% n: 5 2022-04-12 → 2026-05-29 | ARWR Jun avg: 5.19% median: 4.59% win: 75% σ: 6.18% n: 4 2022-04-12 → 2026-05-29 (current) | ARWR Jul avg: 6.87% median: 4.94% win: 50% σ: 10.82% n: 4 2022-04-12 → 2026-05-29 | ARWR Aug avg: -0.92% median: -11.60% win: 25% σ: 27.49% n: 4 2022-04-12 → 2026-05-29 | ARWR Sep avg: 4.57% median: -9.78% win: 25% σ: 35.38% n: 4 2022-04-12 → 2026-05-29 | ARWR Oct avg: 4.76% median: 2.30% win: 50% σ: 13.36% n: 4 2022-04-12 → 2026-05-29 | ARWR Nov avg: 9.60% median: 8.41% win: 50% σ: 23.94% n: 4 2022-04-12 → 2026-05-29 | ARWR Dec avg: 17.13% median: 25.97% win: 75% σ: 31.16% n: 4 2022-04-12 → 2026-05-29 |